PMA supplement
P110019 S075: XIENCE PRIME/LL, XPEDITION, XPEDITION SV,LL, AND ALPINE EVEROLIMUS ELUTING CORONARY STENT SYSTEM
FDA PMA supplement · Panel Track · Abbott Vascular
Key facts
| Original PMA | P110019 |
|---|---|
| Supplement number | S075 |
| Supplement type | Panel Track |
| Reason for the supplement | Labeling Change - Indications/instructions/shelf life/tradename |
| Trade name | XIENCE PRIME/LL, XPEDITION, XPEDITION SV,LL, AND ALPINE EVEROLIMUS ELUTING CORONARY STENT SYSTEM |
| Generic name | Coronary drug-eluting stent |
| Applicant | Abbott Vascular |
| Product code | NIQ |
| Received date | Feb 2, 2015 |
| Decision date | Sep 23, 2015 |
| Docket number | 15M-3516 |
| Notice date | Oct 15, 2015 |
At a glance
- No Expedited review granted
- Yes Approval order on file
- Yes Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: